Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate.
Program Overview
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing ... |
|
Case Studies in Hereditary Angioedema: Moving Beyond Crisis to Long-Term Prevention
Hereditary angioedema (HAE) is an autosomal dominant condition that causes recurring, unpredictable, and potentially fatal attacks resulting in a profound disease burden and diminished health-related quality of life (QoL). Recent advances have led to new therapies for HAE, including long-acting prophylactic therapies that have improved efficacy, tolerability, and convenience, compared to earlier treatments. Many health care providers are unaware of HAE and its diagnosis, particularly the diffe... |